Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2515)	6/15/2009 12:54:19 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AEZS is also doing well in spite of the general market.<g> The stock has had a nice % run since January and is up 28.36% today. The stock only partially closed the UG of March 6, but it has fully closed the more recent one on June1.<g> bigcharts.marketwatch.com It announces that patient follow-up in the open-label safety study of its PIII of cetrorelix pamoate in patients with BPH is scheduled to be completed at the end of this week and the data analysis and reporting will be brought forward from the scheduled 4thQ quarter into the 3rdQ, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study. YHOO has a 'TARGET' OF $3.19 but it seems the stock still could test the $4 level. <g> bigcharts.marketwatch.com Bernard